AMACR and prostate adenocarcinoma: Lastly, another potentially useful immunohistochemical marker for differential diagnosis between CRC and SBA is represented by alpha-methylacyl-CoA racemase (AMACR), a well-known biomarker for prostatic adenocarcinoma, as it has been observed in the majority of CRCs (62%), although it is rarely expressed (4%) in SBAs [24].